Danila Gurgone

Danila Gurgone

Auto-generated profile, based on publicly available information

Danila Gurgone

University of Glasgow

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2020 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
VFValentina Di Francesco
Valentina Di Francesco
DGDanila Gurgone
Danila Gurgone
RPRoberto Palomba
Roberto Palomba
MFMiguel Filipe Moreira Ferreira
Miguel Filipe Moreira Ferreira
TCTiziano Catelani
Tiziano Catelani
Paolo DecuzziPaolo Decuzzi
Paolo Decuzzi

5 March 2019 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
EMEmma Mitidieri
Emma Mitidieri
DGDanila Gurgone
Danila Gurgone
ECElisabetta Caiazzo
Elisabetta Caiazzo
TTTeresa Tramontano
Teresa Tramontano
Carla CicalaCarla Cicala
Carla Cicala
RBRoberta D'EMmanuele di Villa Bianca
Roberta D'EMmanuele di Villa Bianca
Background and Purpose: Among the three enzymes involved in the transsulfuration pathway, only cystathionine β‐synthase (CBS) converts L‐cysteine into L‐serine and H2S. L‐serine is also involved in the de novo sphingolipid biosynthesis through a condensation with palmitoyl‐CoA by the action of serine palmitoyltransferase (SPT). Here, we have investigated if L‐serine contributes to the vasorelaxant effect.Experimental Approach: The presence of CBS in mouse vascular endothelium was assessed by immunohistochemistry and immunofluorescence. The relaxant activity of L‐serine (0.1–300 μM) and L‐cysteine (0.1–300 μM) was estimated on mouse aorta rings, with or without endothelium. A pharmacological modulation study evaluated NO and sphingosine‐1‐phosphate (S1P) involvement. Levels of NO and S1P were also measured following incubation of aorta tissue with either L‐serine (1, 10, and 100 μM) or L‐cysteine (10, 100 μM, and 1 mM).Key Results: L‐serine relaxed aorta rings in an endothelium‐dependent manner. The vascular effect was reduced by L‐NG‐nitro‐arginine methyl ester and wortmaninn. A similar pattern was obtained with L‐cysteine. The S1P1 receptor antagonist (W146) or the SPT inhibitor (myriocin) reduced either L‐serine or L‐cysteine relaxant effect. L‐serine or L‐cysteine incubation increased NO and S1P levels in mouse aorta.Conclusions and Implications: L‐serine, a by‐product formed within the transsulfuration pathway starting from L‐cysteine via CBS, contributes to the vasodilator action of L‐cysteine. The L‐serine effect involves both NO and S1P. This mechanism could be involved in the marked dysregulation of vascular tone in hyperhomocysteinemic patients (CBS deficiency) and may represent a feasible therapeutic target.Linked Articles: This article is part of a themed section on Hydrogen Sulfide in Biology & Medicine. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.4/issuetoc

3 March 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
MSMohsen Shoaran
Mohsen Shoaran
ECElisabetta Caiazzo
Elisabetta Caiazzo
MMMoustafa I. Morsy
Moustafa I. Morsy
DGDanila Gurgone
Danila Gurgone
NMNeil MacRitchie
Neil MacRitchie
PMPasquale Maffia
Pasquale Maffia
Background: Inflammatory chemokine receptors encompassing CCR1, CCR2, CCR3, and CCR5 orchestrate the recruitment of leukocytes during inflammation. In atherosclerosis, there is ongoing controversy surrounding the precise role each inflammatory chemokine receptor plays in the disease process. We thus performed a systematic review and meta‐analysis to examine the effects of inflammatory chemokine receptor inhibition on experimental atherosclerotic burden. Methods: We performed a systematic literature search of PubMed/MEDLINE, Embase, and Web of Science for studies on the pharmacological and/or genetic manipulation of inflammatory chemokine receptors in murine models of atherosclerosis or hyperlipidemia. We extracted data on lesion size and morphological composition as primary outcomes, and plasma lipid profile and mouse body weight as secondary outcomes. We used a random effects model to calculate the pooled effect size across studies as the standardized mean difference (SMD) with 95% CIs. Results: A total of 38 studies of experimental atherosclerosis (CCR1: n=9, CCR2: n=24, CCR5: n=13) were included. Genetic or pharmacological inhibition of CCR2 and CCR5 significantly reduced lesion size (CCR2: SMD=−1.14 [95% CI, −1.47 to −0.81]; CCR5: SMD=−1.06 [95% CI, −1.64 to −0.48]), (CCR2: SMD=−0.72 [95% CI, −1.15 to −0.29]; CCR5: SMD=−1.92 [95% CI, −2.58 to −1.26]) and macrophage load (CCR2: SMD=−1.35 [95% CI, −1.97 to −0.74], CCR5: SMD=−1.29 [95% CI, −2.39 to −0.20]), (CCR2: SMD=−0.86 [95% CI, −1.43 to −0.29]; CCR5: SMD=−1.69 [95% CI, −2.69 to −0.69]), respectively. Pharmacological (but not genetic) targeting of CCR1 significantly reduced lesion size, with protection observed only in males when both approaches were considered. Conclusions: Our analysis suggests that inhibition of either CCR2 or CCR5 is protective in experimental atherosclerosis, while the effect of CCR1 intervention is less clear with potential beneficial effects in male populations.


31 October 2026 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
AGAgnese Graziosi
Agnese Graziosi
MRMaria Antonietta Riemma
Maria Antonietta Riemma
DGDanila Gurgone
Danila Gurgone
ASAlice Schianchi
Alice Schianchi
FMFabiana Morroni
Fabiana Morroni
APArianna Pani
Arianna Pani